SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting

Phase 3

IMA203 vs. Investigator's ChoiceSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Sponsor:

Immatics US, Inc.

Code:

NCT06743126

Conditions

Melanoma, Cutaneous Malignant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IMA203

nivolumab plus relatlimab

lifileucel

nivolumab

pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Immatics US, Inc. on 2025-04-16.